Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Superpixel Pre-segmentation of HER2 Slides for Efficient Annotation (2022) Öttl M, Mönius J, Marzahl C, Rübner M, Geppert CI, Hartmann A, Beckmann M, et al. Conference contribution, Conference Contribution Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial (2022) Graf J, Sickenberger N, Brusniak K, Matthies LM, Deutsch TM, Simoes E, Plappert C, et al. Journal article Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial (2022) Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Journal article Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents (2021) Plank AC, Maschke J, Rohleder N, Fasching P, Beckmann M, Kornhuber J, Eichler A, et al. Journal article Prenatal Androgen Influence on Addictive Behaviour in Adolescence Vorgeburtlicher Androgen- einfluss auf süchtiges Verhalten in der Adoleszenz (2021) Lenz B, Eichler A, Buchholz VN, Fasching P, Kornhuber J Journal article, Review article Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Müller V, Banys-Paluchowski M, Friedl TW, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article A careful reassessment of anthracycline use in curable breast cancer (2021) Hurvitz SA, Mcandrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching P, et al. Journal article, Review article DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Mueller V, et al. Journal article Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (BMC Cancer, (2021), 21, 1, (920), 10.1186/s12885-021-08656-0) (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article, Erratum MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021) Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, et al. Journal article